However, the effects of anti-PD-1 are enhanced by co-treatment with ngTASO by facilitating the infiltration of CTLs throughout the entire tumor, partly mediated by downregulation of the intrinsic active β-catenin and improving the T cell-mediated antitumor immunity, resulting in the enhanced delay of tumor growth. Here, PDCD1 is linked to neoplasm.